Time Magazine Publishes Same-Day Analysis Thursday July 23 Headlined 'An FDA Committee Just Voted in Favor of Peptides Despite the Agency's Opposition'; the Story Frames the 8-6 BPC-157 and KPV Votes as an Unusual Advisory-Panel Override of the FDA Career-Staff Recommendation and Notes That More Than a Half-Dozen New PCAC Members With Peptide-Industry Ties Were Seated Ahead of the Meeting; Washington Times Frames the Same Outcome as 'FDA Panel Narrowly Backs Unapproved Peptide Drug Touted by Joe Rogan and Other Influencers'
Time Magazine published a same-day analysis Thursday July 23, 2026 headlined 'An FDA Committee Just Voted in Favor of Peptides, Despite the Agency's Opposition,' framing the 8-6 votes on BPC-157 and KPV as an unusual advisory-panel override of the FDA career-staff position. The Time analysis notes that before the meeting, more than a half-dozen new PCAC members were added to the panel with documented ties to the peptide industry (physicians, pharmacists, and consultants who work with the substances commercially), a composition change first reported by STAT News on June 29 that has been central to the pre-vote debate. Washington Times ran a parallel same-day feature headlined 'FDA panel narrowly backs unapproved peptide drug touted by Joe Rogan and other influencers,' framing BPC-157 through its influencer-endorsement pathway. ABC News, NPR (nationally syndicated across ~40 public media outlets), the Associated Press, and Time together produced the mainstream media response that PCAC-vote days typically generate for major regulatory decisions. The FDA is expected to review the recommendation and initiate rulemaking; the timeline for actual 503A bulks-list addition is 6-18 months.